Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 2024TransplantationOpen Access

Efficacy and Safety of Bleselumab in Preventing the Recurrence of Primary Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Phase 2a, Randomized, Multicenter Study

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJun ShojiWGWilliam C. GogginsJWJason R. Wellen

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Shoji et al. (2024) studied this question.

synapsesocial.com/papers/68e70da3b6db64358768754ahttps://doi.org/10.1097/tp.0000000000004985
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Combined Anti-CD20/Anti-CD38 Therapy in Posttransplant Focal Segmental Glomerulosclerosis Recurrence: A Retrospective, International, Multicenter Study2026 · 5 citations
  2. 2Prophylactic interventions for focal segmental glomerulosclerosis recurrence after kidney transplantation: a systematic review and network meta-analysis2026
  3. 3Anti-CD38/Anti-CD20 Rescue Therapy for Post-Transplant Recurrent Focal Segmental Glomerulosclerosis2026 · 1 citations
  4. 4Prophylactic treatment of FSGS recurrence in patients who relapsed in a previous kidney graft2024 · 6 citations
  5. 5Rescue with obinutuzumab and daratumumab as combined B cell/plasma cell targeting approach in severe posttransplant focal segmental glomerulosclerosis recurrence2024 · 26 citations